National Cancer Institute Grants Guided Therapeutics, Inc. $2.5 Million to Commercialize Non-Invasive Cervical Cancer Detection Device

Funds to Help Commercialize Painless Test, with Immediate Results, for Cervical
Disease
NORCROSS, Ga.--(Business Wire)--
Guided Therapeutics, Inc. (GT) (Pink Sheets: GTHP) today announced that it was
awarded a $2.5 million matching grant by the National Cancer Institute (NCI) to
bring to market and expand the array features for its LightTouch non-invasive
cervical cancer detection technology. The award provides resources to complete
the regulatory process and begin manufacturing ramp up for the device and
single-patient-use disposable.

"This grant provides significant non-dilutive resources for us to begin
manufacturing LightTouch devices and disposables for an international launch, as
we simultaneously complete the U.S. Food and Drug Administration (FDA)
pre-market approval (PMA) application process," said Mark L. Faupel, Ph.D.,
President and CEO of GT.

Including the new award, the company has been awarded approximately $6 million
in six consecutive grants from the NCI to develop the new, pain-free test for
detecting cervical disease.

"We believe that the grant validates the development of our cost effective
cancer detection technology, as the NCI reviewed a combination of our technical
approach, commercialization plan and clinical performance to date in making the
award," said Shabbir Bambot, Ph.D., Vice-president of Research and Development
for GT and principal investigator of the grant. "Additionally, we believe that
our scientific approach and underlying intellectual property position were key
factors in being awarded this grant."

The GT LightTouch technology systematically and rapidly scans the cervix to
identify cancer and pre-cancer painlessly and non-invasively, by analyzing the
wavelengths of light reflected from cervical tissue. The technology
distinguishes between normal and diseased tissue, by detecting biochemical and
morphological changes at the cellular level. Unlike Pap or HPV tests, the
LightTouch test does not require a tissue sample or laboratory analysis, and is
designed to provide results immediately. The technology is designed as a device
employing a single-use disposable patient interface.

Since development of the technology began, more than 3,000 women have been
tested with the LightTouch, including more than 1,900 women who were evaluated
as part of the FDA pivotal clinical trial.

According to studies published in the peer-reviewed Journal of Lower Genital
Tract Disease, the non-invasive LightTouch test has the potential to be
significantly more accurate when compared to tissue sample-based tests such as
the Pap smear.

About Guided Therapeutics

Guided Therapeutics, Inc. (Pink Sheets: GTHP) is developing a rapid and painless
test for the early detection of disease that leads to cervical cancer. The
technology is designed to provide an objective result at the point of care,
thereby improving the management of cervical disease. Unlike Pap and HPV tests,
the device does not require a painful tissue sample and results are known
immediately. GT also has an agreement with Konica Minolta Opto, Inc. (KMOT) of
Tokyo to co-develop non-invasive products, for the detection of lung and
esophageal cancer based on the company`s LightTouch non-invasive cervical cancer
detection technology. For more information, visit GT`s web site
www.guidedinc.com.

The Guided Therapeutics LightTouch Non-invasive Cervical Cancer Detection Device
is an investigational device and is limited by federal law to investigational
use.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995. A number of the matters and subject areas discussed in this news release
that are not historical or current facts deal with potential future
circumstances and developments. The discussion of such matters and subject areas
is qualified by the inherent risks and uncertainties surrounding future
expectations generally and also may materially differ from Guided Therapeutics`
actual future experience involving any of or more of such matters and subject
areas. Such risks and uncertainties include: the early stage of products in
development, the uncertainty of market acceptance of products, the uncertainty
of development or effectiveness of distribution channels, the intense
competition in the medical device industry, the uncertainty of capital to
develop products, the uncertainty of regulatory approval of products, dependence
on licensed intellectual property, as well as those that are more fully
described from time to time under the heading "Risk Factors" in Guided
Therapeutics` reports filed with the SEC, including Guided Therapeutics` Annual
Report on Form 10-KA for the fiscal year ended December 31, 2008 and subsequent
quarterly reports.

Guided Therapeutics, Inc.
Bill Wells, 770-242-8723

Copyright Business Wire 2009